Clinical trial XT 23-01 - FIPO23
A Phase I/II Open Label, Multiple Dose, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetic and Efficacy of the glyco-humanized polyclonal antibody XON7 in patients with Advanced Solid Tumors
| Trial status | Trial open for recruitment |
|---|---|
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | Xenothera |
| EudraCT Identifier | 2023-505266-29-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06154291 |
| Last update |